<DOC>
	<DOC>NCT00745589</DOC>
	<brief_summary>To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.</brief_summary>
	<brief_title>Sevelamer Hydrochloride in Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Cardiovascular disease accounts for nearly 50% of the mortality and is the most frequent cause of hospitalization in ESRD patients. Hyperphosphatemia is increasingly recognized to be an important predictor of mortality and cardiovascular death in ESRD patients and is largely attributed to the increased prevalence of vascular calcification.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>ESRD patients receiving longterm peritoneal dialysis treatment with hyperphosphatemia currently receiving aluminumbased phosphorus binders or whose phosphorus control remains suboptimal with calciumbased binders only Patients who cannot afford to selfpay sevelamer hydrochloride. Patients who provided informed consent for the study Patients with underlying active malignancy Patients with cyanotic congenital heart disease Patients with poor general condition Patients with plan for living related kidney transplant within coming 1 year Female patients with pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vascular,</keyword>
	<keyword>valvular calcification,</keyword>
	<keyword>phosphate binder,</keyword>
	<keyword>sevelamer,</keyword>
	<keyword>endstage renal disease</keyword>
	<keyword>peritoneal dialysis</keyword>
</DOC>